A limiting factor for the progress of radionuclide-based cancer diagnostics and therapy: Availability of suitable radionuclides

Acta Oncologica

Volumn 43, Issue 3, 2004, Pages 264-275

  Tolmachev, Vladimir ^a   Carlsson, Jörgen ^a   Lundqvist, Hans ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACRIDINE DERIVATIVE; ANTIBODY; ASTATINE 211; BISMUTH; BISMUTH 212; BISMUTH 213; CAPROMAB PENDETIDE IN 111; COPPER 62; COPPER 64; IBRITUMOMAB TIUXETAN; INDIUM 111; IODINE 123; IODINE 125; IODINE 131; LEAD 203; MONOCLONAL ANTIBODY B.72.3; NOFETUMOMAB; OCTREOTATE DERIVATIVE; OCTREOTIDE; ONCOSCINT; PENTETIC ACID; PENTETREOTIDE; PENTETREOTIDE IN 111; RADIOISOTOPE; RUBIDIUM 82; SOMATOSTATIN DERIVATIVE; STEROID; STRONTIUM 82; TECHNETIUM 99M; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; UNINDEXED DRUG; YTTRIUM 90;

ALPHA RADIATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BETA RADIATION; BLADDER CARCINOMA; BLOOD TOXICITY; BREAST CANCER; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER REGRESSION; CLINICAL TRIAL; COLORECTAL CANCER; DIAGNOSTIC ACCURACY; DIGESTIVE SYSTEM TUMOR; DOSIMETRY; DRUG BIOAVAILABILITY; DRUG DNA BINDING; DRUG HALF LIFE; DRUG LABELING; DRUG STABILITY; DRUG STORAGE; DRUG TRANSPORT; FIELD EMISSION; GASTROINTESTINAL CARCINOMA; HEMATOLOGIC DISEASE; HUMAN; IMMUNOSCINTIGRAPHY; INTERMETHOD COMPARISON; KIDNEY CARCINOMA; LIVER METASTASIS; LUNG NON SMALL CELL CANCER; NEUROENDOCRINE TUMOR; NONHODGKIN LYMPHOMA; OVARY CANCER; PANCREAS CARCINOMA; PANCREAS TUMOR; POPULATION DENSITY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITY OF LIFE; RADIODIAGNOSIS; RADIOIMMUNOTHERAPY; RADIOLYSIS; SHELF LIFE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOLID TUMOR; TARGET CELL DESTRUCTION; UTERINE CERVIX CARCINOMA;

ASTATINE; CYCLOTRONS; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; RADIOISOTOPES; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 2942529385     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860410028943     Document Type: Article

References (121)

1. Carlsson J, Forssell-Aronsson E, Hietala SO, Stigbrand T, Tennvall J. Review: Tumour therapy with radionuclides; assessment of progress and problems. Radiother Oncol 2003; 66(2): 107-17.
2. Carlsson J, Forssell-Aronsson E, Glimelius B, Mattsson S. Review: Therapy with radiopharmaceuticals. Acta Oncol 2002; 41(7-8): 623-8.
3. Carlsson J, Forssell-Aronsson E, Glimelius B. Review: Radiation therapy through activation of stable nuclides. Acta Oncol 2002; 41(7-8): 629-34.
4. Volkert WA, Hoffnan TJ. Therapeutic radiopharmaceuticals. Chem Rev 1999; 99: 2269-92.
5. Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med 2002; 43(5): 693-713.
6. Krenning EP, Bakker WH, Breeman WA, Koper JW, Kooij PP, Ausema L, Lameris JS, Reubi JC, Lamberts SW. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1989; 1(8632): 242-4.
7. Lamberts SW, Bakker WH, Reubi JC, Krenning EP. Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med 1990; 323: 1246-9.
8. 1]- octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation. Life Sci 1991; 49: 1583-91.
9. 1]-octreotide for detection of somatostatin receptor-positive tumors in rats. Life Sci 1991; 49: 1593-601.
10. Behr TM, Behe M, Becker W. Diagnostic applications of radiolabeled peptides in nuclear endocrinology. Q J Nucl Med 1999; 43: 268-80.
11. Quintana JC, Blend MJ. The dual-isotope ProstaScint imaging procedure: clinical experience and staging results in 145 patients. Clin Nucl Med 2000; 25: 33-40.
12. Polascik TJ, Manyak MJ, Haseman MK, Gurganus RT, Rogers B, Maguire RT, Partin AW. Comparison of clinical staging algorithms and 111indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients. Cancer 1999; 85: 1586-92.
13. Fang DX, Stock RG, Stone NN, Krynyckyi BR, Kim CK, Machac J. Use of radioimmunoscintigraphy with indium-111-labeled CYT-356 (ProstaScint) scan for evaluation of patients for salvage brachytherapy. Tech Urol 2000; 6: 146-50.
14. Murphy GP, Elgamal AA, Troychak MJ, Kenny GM. Follow-up ProstaScint scans verify detection of occult soft-tissue recurrence after failure of primary prostate cancer therapy. Prostate 2000; 42: 315-7.
15. Manyak MJ, Hinkle GH, Olsen JO, Chiaccherini RP, Partin AW, Piantadosi S, Burgers JK, Texter JH, Neal CE, Libertine JA, Wright GL Jr, Maguire RT. Immunoscintigraphy with indium-111-capromab pendetide: evaluation before definitive therapy in patients with prostate cancer. Urology 1999; 54: 1058-63.
16. Bohdiewicz PJ. Indium-111 satumomab pendetide: the first PDA-approved monoclonal antibody for tumor imaging. J Nucl Med Technol 1998; 26: 155-63.
17. 111In-labelled anti-TAG72 monoclonal antibody. Nucl Med Commun 1999; 20: 123-30.
18. Hughes K, Pinsky CM, Petrelli NJ, Moffat FL, Patt YZ, Hammershaimb L, Goldenberg DM. Use of carcinoembryonic antigen radioimmunodetection and computed tomography for predicting the resectability of recurrent colorectal cancer. Ann Surg 1997; 226: 621-31.
19. Goldenberg DM, Wegener W. Studies of breast cancer imaging with radiolabeled antibodies to carcinoembryonic antigen. Immunomedics Breast Cancer Study Group. Acta Med Austriaca 1997; 24: 55-9.
20. Moffat FL Jr, Gulec SA, Serafini AN, Sfakianakis GN, Pop R, Robinson DS, Franceschi D, Boggs J, Livingstone AS. A thousand points of light or just dim bulbs? Radiolabeled antibodies and colorectal cancer imaging. Cancer Invest 1999; 17: 22-34.
21. Breitz HB, Tyler A, Bjorn MJ, Lesley T, Weiden PL. Clinical experience with Tc-99m nofetumomab merpentan Verluma radioimmunoscintigraphy. Clin Nucl Med 1997; 22: 615-20.
22. Grillo-Lopez AJ, Zevalin. The first radioimmunotherapy approved for the treatment of lymphoma. Expert Rev Anticancer Ther 2002; 2(5): 485-93.
23. Garber K. ODAC panel gives nod to Bexxar. J Natl Cancer Inst 2003 Feb 5; 95(3): 189.
24. Goldenberg DM. Advancing role of radiolabeled antibodies in the therapy of cancer. Cancer Immunol Immunother 2003; 52(5): 281-96.
25. Dillman RO. Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma. J Clin Oncol 2002; 20(16): 3545-57.
26. Juweid ME. Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice. J Nucl Med 2002; 43(11): 1507-29.
27. Cheson BD. Radioimmunotherapy of non-Hodgkin lymphomas. Blood 2003; 101(2): 391-8.
28. Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN, Cripe L, Wiseman G, Olejnik T, Multani PS, White CA. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002; 20(15): 3262-9.
29. De Jong M, Breeman WA, Bernard HF, Kooij PP, Slooter GD, Van Eijck CH, Kwekkeboom DJ, Valkema R, Macke HR, Krenning EP. Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues. Q J Nucl Med 1999; 43(4); 356-66.
30. 111In-pentetreotide. State of the art and perspectives. Q J Nucl Med 2000; 44(1): 88-95.
31. Anthony LB, Woltering EA, Espenan GD, Cronin MD, Maloney TJ, McCarthy KE. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med 2002; 32(2): 123-32.
32. 111In-Octreotide therapy in patients with disseminated neuroendocrine tumours. Nucl Med Commun 2000; 21(1): 97-102.
33. Chinol M, Bodei L, Cremonesi M, Paganelli G. Receptor-mediated radiotherapy with Y-DOTA-DPhe-Tyr-octreotide: the experience of the European Institute of Oncology Group. Semin Nucl Med 2002; 32(2): 141-7.
34. 90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 2001; 12(7): 941-5.
35. 90Y-DOTA-D-Phe1-Tyr3-octreotide. Eur J Nucl Med 2001; 28(4): 426-34.
36. Waldherr C, Pless M, Maecke HR, Schumacher T, Crazzolara A, Nitzsche EU, Haldemann A, Mueller-Brand J. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 2002; 43(5): 610-6.
37. Kwekkeboom DJ, Bakker WH, Kam BL, Teunissen JJM, Kooij PPM, Herder WW, Feelders RA, Eijck CHJ, Jong M, Srinivasan A, Erion JL, Krenning EP. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [Lu-177-DO-TA(0),Tyr(3)]octreotate. Eur J Nucl Med Molec Im 2003; 30: 417-22.
38. Newsline. Future of nuclear medicine, part 3: Assessment of the U.S. Therapeutic Radiopharmaceuticals Market (2001-2002). J Nucl Med 1998; 39: N14-27.
39. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 2003; 30(5): 781-93.
40. Wilbur DS. Radiohalogenation of proteins: an overview of radionuclides, labeling methods, and reagents for conjugate labeling. Bioconjug Chem 1992; 3: 433-70.
41. Wheldon TE, O'Donoghue JA. The radiobiology of targeted radiotherapy. Int J Radiat Biol 1990; 58: 1-21.
42. 90Y. Radiother Oncol 1991; 21(2): 91-9.
43. O'Donoghue JA, Wheldon TE. Targeted radiotherapy using Auger electron emitters. Phys Med Biol 1996; 41: 1973-92.
44. Kearney T, Hughes A, Hanson RN, DeSombre ER. Radiotoxicity of Auger electron-emitting estrogens in MCF-7 spheroids: a potential treatment for estrogen receptor-positive tumors. Radiat Res 1999; 151: 570-9.
45. 125IUdR loaded biodegradable microspheres for controlled delivery to the brain. J Microencapsul 1998; 15: 789-801.
46. 125I]iodo-2′-deoxyuridine in the radiotherapy of brain tumors in rats. J Nucl Med 1998; 39: 1148-54.
47. Rotmensch J, Atcher RW, Hines J, Toohill M, Herbst AL. Comparison of short-lived high-LET alpha-emitting radionuclides lead-212 and bismuth-212 to low-LET X-rays on ovarian carcinoma. Gynecol Oncol 1989; 35: 297-300.
48. Rotmensch J, Schwartz JL, Atcher RW, Harper PV, DeSombre E. Increased nuclear damage by high linear energy transfer radioisotopes applicable for radiodirected therapy against radiologic malignancies. Gynecol Obstet Invest 1991; 32: 180-4.
49. Cunningham SH, Mairs RJ, Wheldon TE, Welsh PC, Vaidyanathan G, Zalutsky MR. Toxicity to neuroblastoma cells and spheroids of benzylguanidine conjugated to radionuclides with short-range emissions. Br J Cancer 1998; 77: 2061-8.
50. 90Y-labeled CO17-1A Fab′ fragments in a human colonic cancer model. Cancer Res 1999; 59: 2635-43.
51. Zalutsky MR, Vaidyanathan G. Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy. Curr Pharm Des 2000; 6: 1433-55.
52. Zweit J. Radionuclides and carrier molecules for therapy. Phys Med Biol 1996; 41: 1905-14.
53. Matthews DC. Immunotherapy in acute myelogenous leukemia and myelodysplastic syndrome. Leukemia 1998; 12(Suppl. 1): S33-6.
54. 213Bi- alpha radioimmunotherapy for multiple myeloma. Clin Cancer Res 1999; 5(Suppl. 10): 3165s-70s.
55. Huneke RB, Pippin CG, Squire RA, Brechbiel MW, Gansow OA, Strand M. Effective alpha-particle-mediated radioimmunotherapy of murine leukemia. Cancer Res 1992; 52: 5818-20.
56. Jurcic JG, Caron PC, Nikula TK, Papadopoulos EB, Finn RD, Gansow OA, Miller WH Jr, Geerlings MW, Warrell RP Jr, Larson SM. Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias. Cancer Res 1995; 55: 5908s-10s.
57. Hartmann F, Horak EM, Garmestani K, Wu C, Brechbiel MW, Kozak RW, Tso J, Kosteiny SA, Gansow OA, Nelson DL. Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody 212Bi-anti-Tac. Cancer Res 1994; 54: 4362-70.
58. 213Bi-HuM195 (anti-CD33) in patients with leukemia. J Nucl Med 1999; 40: 1935-46.
59. 213Bi: the role of tumor necrosis factor alpha in the development of pulmonary fibrosis. Clin Cancer Res 1999; 5: 3160s-4s.
60. 213Bi. Br J Cancer 1999; 80: 175-84.
61. Kennel SJ, Lankford TK, Foote LJ, Davis IA, Boll RA, Mirzadeh S. Combination vascular targeted and tumor targeted radioimmunotherapy. Cancer Biother Radiopharm 1999; 14: 371-9.
62. McDevitt MR, Sgouros G, Finn RD, Humm JL, Jurcic JG, Larson SM, Scheinberg DA. Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med 1998; 25: 1341-51.
63. Lambrecht RM, Mirzadeh S. Cyclotron isotopes and radiopharmaceuticals. Astatine-211. Int J Appl Radiat Isot 1985; 36: 443-6.
64. Talback M, Stenbeck M, Rosen M, Barlow L, Glimelius B. Cancer survival in Sweden 1960-1998 - developments across four decades. Acta Oncol 2003; 42(7): 637-59.
65. Holmes EH. PSMA specific antibodies and their diagnostic and therapeutic use. Expert Opin Investig Drugs 2001; 10(3): 511-9.
66. Essand M, Gronvik C, Hartman T, Carlsson J. Radioimmunotherapy of prostatic adenocarcinomas: effects of 1311-labelled E4 antibodies on cells at different depth in DU 145 spheroids. Int J Cancer 1995; 63(3): 387-94.
67. Blackledge G, Averbuch S, Kay A, Barton J. Anti-EGF receptor therapy. Prostate Cancer Prostatic Dis 2000; 3(4): 296-302.
68. Sakamoto J, Kojima H, Kato J, Hamashima H, Suzuki H. Organ-specific expression of the intestinal epithelium-related antigen A33, a cell surface target for antibody-based imaging and treatment in gastrointestinal cancer. Cancer Chemother Pharmacol 2000; 46 Suppl: S27-32.
69. Hammarstrom S. The carcinoembryonic antigen CEA family: structures, suggested functions and expression in normal and malignant tissues. Sem Cancer Biol 1999; 9(2): 67-81.
70. b, X, and Y blood group antigens in human colonie tumors and normal tissue and in human tumor-derived cell lines. Cancer Res 1986; 46(3): 1553-61.
71. Cardillo MR, Castagna G, Memeo L, De Bernardinis E, Di Silverio F. Epidermal growth factor receptor, MUC-1 and MUC-2 in bladder cancer. J Exp Clin Cancer Res 2000; 19(2): 225-33.
72. Balzar M, Winter MJ, de Boer CJ, Litvinov SV. The biology of the 17-1A antigen (Ep-CAM). J Mol Med 1999; 77(10): 699-712.
73. Lee JC, Wang ST, Chow NH, Yang HB. Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery. Eur J Cancer 2002; 38(8): 1065-71.
74. b antigens with survival in patients with carcinoma of the lung. N Engl J Med 1992; 327(1): 14-8.
75. Bunn PA, Franklin W. Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer. Semin Oncol 2002; 29(5 Suppl 14); 38-44.
76. Zinner RG, Kim J, Herbst RS. Non-small cell lung cancer clinical trials with trastuzumab: their foundation and preliminary results. Lung Cancer 2002; 37(1): 17-27.
77. Kaptain S, Tan LK, Chen B. Her-2/neu and breast cancer. Diagn Mol Pathol 2001; 10(3): 139-52.
78. Braun S, Hepp F, Sommer HL, Pantel K. Tumor-antigen heterogeneity of disseminated breast cancer cells: implications for immunotherapy of minimal residual disease. Int J Cancer 1999; 84(1): 1-5.
79. Baselga J, Mendelsohn J. The epidermal growth factor receptor as a target for therapy in breast carcinoma. Breast Cancer Res Treat 1994; 29(1): 127-38.
80. Bue P, Wester K, Sjostrom A, Holmberg A, Nilsson S, Carlsson J, Westlin JE, Busch C, Malmstrom PU. Expression of epidermal growth factor receptor in urinary bladder cancer metastases. Int J Cancer 1998; 76(2): 189-93.
81. Wester K, Sjostrom A, de la Torre M, Carlsson J, Malmstrom PU. HER-2 - a possible target for therapy of metastatic urinary bladder carcinoma. Acta Oncol 2002; 41(3): 282-8.
82. Wiseman G, White C, Sparks R, et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin® radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Crit Rev Oncol Hematol 2001; 39: 181-94.
83. Forssell-Aronsson EB, Nilsson O, Bejegard SA, Kolby L, Bernhardt P, Molne J, Hashemi SH, Wangberg B, Tisell LE, Ahlman H. 111In-DTPA-D-Phe1-octreotide binding and somatostatin receptor subtypes in thyroid tumors. J Nucl Med 2000; 41: 636-42.
84. 3]octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer 2001; 92: 628-33.
85. deHerder WW, Lamberts SW. Somatostatin and somatostatin analogues: diagnostic and therapeutic uses. Curr Opin Oncol 2002; 14: 53-7.
86. Heppeler A, Froidevaux S, Eberle AN, Maecke HR. Receptor targeting for tumor localisation and therapy with radiopeptides. Curr Med Chem 2000; 7: 971-94.
87. Behr TM, Gotthardt M, Barth A, Behe M. Imaging tumors with peptide-based radioligands. Q J Nucl Med 2001; 45: 189-200.
88. Wikstrand CJ, Cokgor I, Sampson JH, Bigner DD. Monoclonal antibody therapy of human gliomas: current status and future approaches. Cancer Metastasis Rev 1999; 18: 451-64.
89. Visser GWM, Diemer EL, Kaspersen FM. The nature of astatine-protein bond. Int J Appl Radiat Isot 1981; 32: 905-12.
90. Zalutsky MR, Narula AS. Astatination of proteins using an N-succinimidyl tri-n-butylstannyl benzoate intermediate. Appl Radiat Isot 1988; 39: 227-32.
91. 2 fragment. Cancer Res 1990; 50: 3514-20.
92. 125I]iodobenzoyl conjugate. Bioconjug Chem 1991; 2: 171-9.
93. Lindegren S, Andersson H, Back T, Jacobsson L, Karlsson B, Skarnemark G. High-efficiency astatination of antibodies using N-iodosuccinimide as the oxidising agent in labelling of N-succinimidyl 3-(trimethylstannyl)benzoate. Nucl Med Biol 2001; 28(1): 33-9.
94. 211At]astato-3-pyridinecarboxylate. Nucl Med Biol 1999; 26: 405-11.
95. Lewis JS, Lewis MR, Cutler PD, Srinivasan A, Schmidt MA, Schwarz SW, Morris MM, Miller JP, Anderson CJ. Radiotherapy and dosimetry of 64Cu-TETA-Tyr3-octreotate in a somatostatin receptor-positive, tumor-bearing rat model. Clin Cancer Res 1999; 5: 3608-16.
96. Buchsbaum DJ, Rogers BE, Khazaeli MB, Mayo MS, Milenic DE, Kashmiri SV, Anderson CJ, Chappell LL, Brechbiel MW, Curiel DT. Targeting strategies for cancer radiotherapy. Clin Cancer Res 1999; 5(Suppl. 10): 3048s-55s.
97. 64Cu-labeled monoclonal antibody 1A3 in a colon cancer model. Clin Cancer Res 1999; 5(Suppl. 10): 3207s-12s.
98. 64Cu using a biomedical cyclotron. Nucl Med Biol 1997; 24: 35-43.
99. Kairemo KJ, Ramsay HA, Tagesson M, Jekunen AP, Paavonen TK, Jaaskela-Saari HA, Liewendahl K, Ljunggren K, Savolainen S, Strand SE. Indium-111 bleomycin complex for radiochemotherapy of head and neck cancer-dosimetric and biokinetic aspects. Eur J Nucl Med 1996; 23: 631-8.
100. Howell RW, Goddu SM, Rao DV. Proliferation and the advantage of longer-lived radionuclides in radioimmunotherapy. Med Phys 1998; 25: 37-42.
101. 114mIn, a candidate for radionuclide therapy: low-energy cyclotron production and labeling of DTPA-D-phe-octreotide. Nucl Med Biol 2000; 27: 183-8.
102. Emran AM, Phillips DR. Biomedical use of arsenic radioisotopes. In: Emran AM, ed. New trends in radiopharmaceutical synthesis, quality assurance, and regulatory control. New York: Plenum Press; 1991. p. 153.
103. Lubberink M, Lundqvist H, Westlin JE, Tolmachev V, Schneider H, Lovqvist A, Sundin A, Carlsson J. Positron emission tomography and radioimmunotargeting - aspects of quantification and dosimetry. Acta Oncol 1999; 38(3): 343-9.
104. 76As]As-arsonic acid and investigation of their stability. J Labelled Comp Radiopharm 1999; 42(Suppl. 1): 759-61.
105. DeSombre ER, Hughes A, Landel CC, Greene G, Hanson R, Schwartz JL. Cellular and subcellular studies of the radiation effects of Auger electron-emitting estrogens. Acta Oncol 1996; 35: 833-40.
106. 125I]iodo-17 beta-estradiol. J Cancer Res Clin Oncol 1993; 119: 207-14.
107. 111In-labeled EGF is selectively radiotoxic to human breast cancer cells over-expressing EGFR. J Nucl Med 2000; 41: 429-38.
108. Hornick CA, Anthony CT, Hughey S, Gebhardt BM, Espenan GD, Woltering EA. Progressive nuclear translocation of somatostatin analogs. J Nucl Med 2000; 41: 1256-63.
109. Bohl Kullberg E, Bergstrand N, Carlsson J, Edwards K, Johnsson M, Sjoberg S, Gedda L. Development of EGF-conjugated liposomes for targeted delivery of boronated DNA-binding agents. Bioconjug Chem 2002; 13(4): 737-43.
110. Orlova A, Koziorowski J, Henssen C, Ghaneolhosseini H, Lundqvist H, Tolmachev V, Sjöberg S. Radiolabelling of acridines with potential use in cancer therapy. Journal of Labelled Compounds and Radiopharaceuticals 1999; 42(Suppl.): 738-40.
111. Lundqvist H, Lubberink M, Tolmachev Y. Positron Emission Tomography. Eur J Physics 1998; 19: 537-52.
112. Goldsmith SJ, Kostakoglu L. Nuclear medicine imaging of lung cancer. Radiol Clin North Am 2000; 38: 511-24.
113. Erasmus JJ, Patz EF Jr. Positron emission tomography imaging in the thorax. Clin Chest Med 1999; 20: 715-24.
114. 82Rb generator in clinical PET studies. Int J Rad Appl Instrum B 1990; 17: 763-8.
115. Herrero P, Hartman JJ, Green MA, Anderson CJ, Welch MJ, Markham J, Bergmann SR. Regional myocardial perfusion assessed with generator-produced copper-62-PTSM and PET. J Nucl Med 1996; 37: 1294-300.
116. Tadamura E, Tamaki N, Okazawa H, Fujibayashi Y, Kudoh T, Yonekura Y, Magata Y, Nohara R, Sasayama S, Konishi J. Generator-produced copper-62-PTSM as a myocardial PET perfusion tracer compared with nitrogen-13-ammonia. J Nucl Med 1996; 37: 729-35.
117. 85Rb. Int J Appl Radiat Isot 1979; 31: 141-51.
118. 62Cu-PTSM. J Nucl Med 2000; 41: 309-14.
119. Lundqvist H, Tolmachev V. Targeting peptides and positron emission tomography. Biopolymers 2002; 66(6): 381-92.
120. Pagani M, Stone-Elander S, Larsson SA. Alternative positron emission tomography with non-conventional positron emitters: effects of their physical properties on image quality and potential clinical applications. Eur J Nucl Med 1997; 24: 1301-27.
121. Glaser M, Luthra SK, Brady F. Review. Applications of positron-emitting halogens in PET-oncology. Int J Oncol 2003; 22: 253-67.